Showing results (581-590 of 727) with videos related to
Sort By:
Pageof 73
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyS Gadgeel, S Peters, T Mok, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|June 22, 2019
Acyclic Stereocontrol in the Additions of Nucleophilic Alkenes to α-Chiral N-Sulfonyl IminesLucas C Moore, Anna Lo, Jason S Fell, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA T Shaw, A M Varghese, B J Solomon, et al.Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.Annals of the Rheumatic Diseases|April 5, 2008
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesE Keystone, P Emery, C G Peterfy, et al.Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.Pageof 73